

# George F Wohlford

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5110407/publications.pdf>

Version: 2024-02-01

28  
papers

963  
citations

623734

14  
h-index

501196

28  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1335  
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of Acute and Recurrent Pericarditis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 76-92.	2.8	197
2	Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2020, 9, e014941.	3.7	150
3	IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018, 11, e005036.	3.9	129
4	Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. <i>Diabetes Care</i> , 2017, 40, 1733-1738.	8.6	98
5	Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II-III Systolic Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 49-60.	1.9	65
6	Rationale and design of the Virginia Commonwealth University Anakinra Remodeling Trial 3 (VCU-ART3): A randomized, placebo-controlled, double-blind, multicenter study. <i>Clinical Cardiology</i> , 2018, 41, 1004-1008.	1.8	41
7	Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 503-510.	3.0	37
8	Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: A subgroup analysis of high-risk ACCORDION trial participants. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1499-1502.	4.4	36
9	Alirocumab in Acute Myocardial Infarction: Results From the Virginia Commonwealth University Alirocumab Response Trial (VCU-AlirocRT). <i>Journal of Cardiovascular Pharmacology</i> , 2019, 74, 266-269.	1.9	24
10	C-Reactive Protein and N-Terminal Pro-brain Natriuretic Peptide Levels Correlate With Impaired Cardiorespiratory Fitness in Patients With Heart Failure Across a Wide Range of Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 178.	2.4	21
11	Pharmacokinetics of L-Triiodothyronine in Patients Undergoing Thyroid Hormone Therapy Withdrawal. <i>Thyroid</i> , 2019, 29, 1371-1379.	4.5	21
12	Metabolic modulation predicts heart failure tests performance. <i>PLoS ONE</i> , 2019, 14, e0218153.	2.5	20
13	Acute Effects of Interleukin-1 Blockade Using Anakinra in Patients With Acute Pericarditis. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 50-52.	1.9	20
14	Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2019, 21, 16.	4.8	16
15	Inflammation and Hypertension. <i>Hypertension</i> , 2020, 75, 297-298.	2.7	15
16	Stenting techniques for coronary bifurcation lesions: Evidence from a network meta-analysis of randomized clinical trials. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E306-E318.	1.7	13
17	Determinants of Cardiorespiratory Fitness in Patients with Heart Failure Across a Wide Range of Ejection Fractions. <i>American Journal of Cardiology</i> , 2020, 125, 76-81.	1.6	10
18	Potential role for interleukin-1 in the cardio-renal syndrome. <i>European Journal of Heart Failure</i> , 2019, 21, 385-386.	7.1	9

#	ARTICLE	IF	CITATIONS
19	A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers. PLoS ONE, 2021, 16, e0247357.	2.5	7
20	Comparison of Cardiorespiratory Fitness in Black or African American Versus Caucasian Patients With Heart Failure. Journal of Cardiopulmonary Rehabilitation and Prevention, 2022, 42, 39-44.	2.1	6
21	Clinical trial enrollment at a rural satellite hospital during COVID-19 pandemic. Journal of Clinical and Translational Science, 2021, 5, e136.	0.6	6
22	In-Hospital Initiation of Sacubitril/Valsartan: A New PARADIGM for Acute Decompensated Heart Failure?. Journal of Cardiovascular Pharmacology, 2019, 74, 1-3.	1.9	5
23	COLCOT and CANTOS: piecing together the puzzle of inflammation and cardiovascular events. Minerva Cardioangiologica, 2020, 68, 5-8.	1.2	5
24	Sacubitrilâ€“Valsartan for the Treatment of Heart Failure. Journal of Cardiovascular Pharmacology, 2020, 75, 105-107.	1.9	4
25	Preservation of Cardiac Reserve and Cardiorespiratory Fitness in Patients With Acute De Novo Versus Acute on Chronic Heart Failure With Reduced Ejection Fraction. American Journal of Cardiology, 2021, 158, 74-80.	1.6	3
26	Response to Comment on Buckley et al. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. Diabetes Care 2017;40:1733â€“1738. Diabetes Care, 2018, 41, e86-e87.	8.6	2
27	Acute Effects of Liothyronine Administration on Cardiovascular System and Energy Metabolism in Healthy Volunteers. Frontiers in Endocrinology, 2022, 13, 843539.	3.5	2
28	Effect of Extracorporeal Membrane Oxygenation Support on the Plasma Levels of Commonly Utilized Catecholamines. ASAIO Journal, 2021, 67, e204-e206.	1.6	0